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resumo 
 
Este relatório tem como objetivo descrever a minha experiência durante os 9 
meses de estágio curricular na Eurotrials, Consultores Científicos, como 
parte do 2º ano do Mestrado de Biomedicina Farmacêutica.  
 
O estágio focou-se maioritariamente no desenvolvimento de competências e 
obtenção de experiência em atividades de Medical Writing, através da 
participação ativa em atividades usualmente desenvolvidas por medical 
writers: escrita, preparação e submissão de artigos científicos, preparação 
de pósters científicos, complilação de apêndices para Clinical Study Reports, 
e escrita de material educativo.  
 
Durante o estágio, tive a oportunidade de adquirir conhecimentos essenciais 
relacionados com a atividade de Medical Writing, e de perceber de forma 
clara o seu papel na investigação clínica, como ferramenta essencial na 
interpretação, descrição e divulgação dos dados obtidos.   
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abstract 
 
This report aims at describing my experience uring the 9 months of curricular 
internship at Eurotrials, Scientific Consultants, as part of the 2nd year of the 
Master’s in Pharmaceutical Medicine.  
 
The internship was mainly focused on the development of skills and 
acquiring experience in Medical Writing activities, trought actively 
participating in activities usually developed by medical writers: writing, 
preparation and submission of scientific articles, preparation of scientific 
posters, compilation of appendices for Clinical Study Reports, and writing of 
educational material.  
 
Throughout the internship, I had the opportunity to acquire valuable 
knowledge related to Medical Writing, as well as to clearly understand its role 
in clinical research, as an essential tool to interpret, describe and publish the 
data obtained.  
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1. Introduction  
This report is an overview of the 9-month internship as a Clinical Data trainee at the Medical Writing 
and Biostatistics Sub-Units (SUs) of Eurotrials, Scientific Consultants, which took place between 
September 2015 and May 2016. The internship was a part of the second year’s curricular activities 
of the Master’s Degree in Pharmaceutical Medicine by the University of Aveiro, Portugal.  
As a Clinical Data trainee, I was actively involved in both medical writing and biostatistics activities, 
though my participation was considerably more frequent in the Medical Writing SU. In this 
document, I describe the tasks performed during the internship, as well as my objectives and overall 
evaluation of this training experience.  
This internship was conducted under the supervision of Luís Veloso, Medical Writing Manager at 
Eurotrials Scientific Consultants, Catarina Silva, Biostatistics Manager at Eurotrials, Scientific 
Consultants, and Professor Vera Afreixo, Assistant Professor at the Department of Mathematics of 
the University of Aveiro. 
 
1.1 Objectives  
The objectives set for this curricular internship included: 
 Primary objective:  
› To acquire knowledge and experience in the tasks associated with the projects and 
services falling under the scope of Medical Writing and Biostatistics. 
 Secondary objectives: 
› To apply and build upon the knowledge acquired during the Bachelor’s Degree in 
Biomedical Sciences and the Master’s Program in Pharmaceutical Medicine. 
› To improve the soft skills needed to successfully work in a professional and team-
based environment, such as communication skills, autonomy, proactivity, 
accountability and assertiveness. 
› To understand the functioning of a Clinical Research Organization (CRO) and their 
role in clinical research. 
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1.2 Report Structure  
In addition to the introduction, this report is divided into five main chapters, briefly described 
below: 
 Chapter 2 – Overview of the host Institution: describes Eurotrials, defining its role in the 
clinical research framework, its purpose, organization and services provided. The Medical 
Writing SU is described in more detail, as the majority of activities performed during my 
internship were related to this department. 
 Chapter 3 – State-of-the-art: describes the state-of-the-art in clinical studies, CRO business, 
medical writing and the peer-review process. 
 Chapter 4 – Training experience: describes the initial training period performed at 
Eurotrials, which provided the basis for the development of various practical activities, as 
well as the Medical Writing and Biostatistics activities performed throughout the 
internship.  
 Chapter 5 – Discussion: provides a discussion of the main learning points of the internship, 
the difficulties faced, and the strategies adopted to overcome them.  
 Chapter 6 – Conclusion: provides final considerations regarding the curricular internship 
and the achievement of its objectives.  
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2. Overview of the host Institution: Eurotrials, Scientific Consultants  
Eurotrials, Scientific Consultants, is a Portuguese, private CRO founded in 1995 in Lisbon by 
members of academia, medical community and pharmaceutical industry (1). It has a strong local 
expertise in Europe and Latin America, with offices in Portugal, Spain, Brazil, Argentina, Chile and 
Mexico (1). 
Eurotrials is composed by multidisciplinary project teams including Project Managers, Clinical 
Research Associates, Study-Start-up and Regulatory Specialists, Data Managers, Statisticians and 
Medical Writers, that provide the integrated support of a full-service CRO (2). As such, Eurotrials 
offers a wide range of services in the areas of health and clinical research, including consulting and 
training services (3). Its various departments have the necessary experience and expertise to 
participate in all stages of a drug, biological product or medical device development (3). 
Eurotrials is organized in different SUs, divided into Business Units (BUs) (Clinical Trials, Real World 
& Outcomes Research, and Regulatory & Data Sciences BUs) and Support Units (Quality Assurance, 
Contracts & Proposals, and Teaching & Training). The Eurotrials Portugal’s internal organization is 
described in Figure 1.  
 
Figure 1 – Eurotrials Portugal’s organizational chart (Courtesy of Eurotrials, Scientific Consultants).  
4 
 
2.1 Overview of the Medical Writing Sub-Unit 
My internship mainly focused on the Medical Writing SU, which is a part of the Clinical Data 
Operational Area.  This department is responsible for writing different types of technical documents 
and scoping several therapeutic areas in various geographic regions, namely in European and Latin 
American regions (4). The Medical Writing SU is a well-experienced, dedicated and organized team 
offering several medical writing services, such as (4):  
 Design and revision of clinical study synopsis (including providing support to define the 
strategies for the product clinical development); 
 Design or revision of clinical study protocols; 
 Writing scientific articles, including original papers, reviews, and others; 
 Submission of articles to journals, comprising the support in the selection of the most 
adequate journal and in the peer review process; 
 Writing and revision of abstracts and posters to congresses or other events; 
 Planning, conducting and reporting of expert Panel/advisory boards; 
 Development of clinical study reports (CSR) in accordance with the applicable ICH 
guidelines and regulatory requirements; 
 Variables definition for data collection tools, including case report forms, patient reported 
outcomes, surveys; 
 Writing of informed consent forms and other documentation addressed to the patient; 
 Replies to opinions issued by health authorities and ethics committees; 
 Literature search for systematic reviews as a background for potential studies, as well as in 
the scope of health technology assessment studies. 
All documents developed by the Medical Writing SU comply with the applicable national and 
international regulatory requirements, including those from Food and Drug Administration (FDA) 
and European Medicines Agency (EMA), and universally accepted guidelines, such as the 
International Conference on Harmonization (ICH)-Good Clinical Practice (GCP), Consolidated 
Standards of Reporting Trials (CONSORT) and Strengthening of the Reporting of Observational 
Studies in Epidemiology (STROBE) (4).  
Currently, the distribution of projects by therapeutic area under the responsibility of Eurotrials’ 
Medical Writing SU is presented in Figure 2. 
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Figure 2 – Number of projects under the responsibility of Eurotrials’ Medical Writing Unit by therapeutic area. 
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3. State-of-the-art 
As my internship took place in a CRO, this chapter provides an overview of clinical research studies 
and of these research organizations, describing their role in clinical research and the evolution of 
the services outsourced. Additionally, to contextualize the activities performed during my 
internship, the medical writing landscape is also described, with a special focus on the various types 
of medical writing, the peer-review process and important guidelines in this field.  
 
3.1 Clinical Research Studies 
Clinical studies may be divided into two large groups: interventional (or experimental) and 
observational studies (5). In interventional studies there is an experimental intervention of the 
investigators upon the study participants, which generally involves the administration of a given 
drug, although non-therapeutic interventions may also be applied (such as a new approach at 
conducting a medical consultation) (6). Observational studies do not involve an experimental 
intervention, but instead the observation of the relationships between factors and outcomes of 
interest (5,6). Both types of studies are described in the sections below. 
 
3.1.1 Interventional studies  
The most common type of interventional studies are the clinical trials. The ICH GCP E6(R1) defines 
a clinical trial as “any investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to 
identify any adverse reactions to an investigational product(s) and/or to study absorption, 
distribution, metabolism, and excretion of an investigational product(s) with the object of 
ascertaining its safety and/or efficacy”. Clinical trials, and more specifically the randomized 
controlled trials (RCTs), are an essential component of the drug development process. They are 
characterized by (7,8): 
 Randomization – ensures that the assignment to treatment groups is arbitrary, balanced, 
and not influenced by patients’ characteristics or physicians’ preferences. 
 Blinding – minimizes the risk of bias when comparing treatments 
 Prospective treatment assignment – ensures that the outcome is preceded by the 
intervention, allowing the evaluation of causation. 
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These features make clinical trials the most reliable tool for establishing a causal relationship 
between intervention and outcome.  
Conventionally, clinical trials have been classified according to four temporal phases (Phases I to 
IV), which correspond to the phases of development of a drug. Nonetheless, this classification does 
not represent the most accurate basis for classifying clinical trials (as recognized by ICH), since the 
same type of trial can occur in different phases of drug development. Alternatively, a classification 
system based on study objectives is preferable, dividing clinical trials in the following categories(9): 
 Human Pharmacology: generally conducted during the first phase of a drug development, 
when a new drug is first administered in humans. They aim to assess a drug’s 
pharmacokinetics and pharmacodynamics, its tolerability, determine its metabolism and 
drug interactions, and make initial estimates of activity. 
 Therapeutic Exploratory: these studies aim to explore the therapeutic efficacy of the drug 
in a selected group of members of a target population. The most adequate dosages to be 
used in later studies are also determined. 
 Therapeutic Confirmatory: aimed to demonstrate/confirm the therapeutic efficacy of a 
drug. They involve larger patient populations and allow the collection of data to confirm 
the safety and efficacy information collected in previous studies. They are intended to 
provide an adequate basis for marketing approval. 
 Therapeutic Use: conducted after drug approval, these trials can be any of the types 
described above, including studies not deemed necessary for marketing approval, but 
which are considered important to optimize drug use.  
 
3.1.2 Observational studies  
Investigators use observational studies to draw inferences on the effect of an “exposure” or 
intervention on a group of subjects by directly observing the individuals in their natural setting (10). 
In these studies, the investigators do not control the intervention they are observing and do not 
manipulate the assignment of subjects to groups (such as by randomization). Instead, the practice 
patterns or policy decisions determine which subjects receive the intervention (6).  
Observational studies allow investigators to study and identify correlations between variables, such 
as between patient characteristics or therapies and a given outcome. There are several types of 
observational study designs, such as: 
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 Cross-sectional studies: these studies consist in the evaluation of a population, 
represented by the study sample, at a single point in time. The samples are selected in 
regards to their exposure status, and without considering their outcome status (which is 
obtained after the enrollment of the patients). They are frequently used to assess the 
association between a particular exposure and the outcome, but also to determine a given 
prevalence in the target population (such as the prevalence of a disease) (5).   
 Case-control studies: in this type of design, the study participants are selected based on 
their status (i.e., with a given disease [cases] or without [controls]) and the past exposure 
to risk factors of interest are explored in both groups to determine the ones contributing 
to the disease development. By quantifying the number of individuals among the cases and 
controls who were exposed to a given risk factor, it is possible to statistically explore the 
associations between the exposure and outcome (5,6).  
 Cohort studies: an example of a cohort study is the prospective follow-up of two groups, 
one exposed to a given risk factor and the other without the exposure, while recording the 
occurrence of new cases (incidence) of a disease, for example, during a predefined follow-
up period (6).    
Data for observational research may have two distinct origins: when data is collected for the specific 
purpose of answering the study’s objectives, it is considered primary data; when data has already 
been collected for other reasons but is used to answer a new research question, it is considered 
secondary data (10).  
Naturally, observational studies have limitations when comparing with clinical trials, such as the 
lack of blinding and randomization, which increase confounding. Nonetheless, well-designed 
observational studies are of utmost importance to understand a particular exposure-outcome 
association. Whereas the tight controlled environment of clinical trials means that many practical 
issued encountered in routine clinical practice are not observed (such as patients with concomitant 
medications and comorbidities), observational studies allow to evaluate the efficacy, safety, 
tolerability and compliance in a larger and more heterogeneous populations, as well as to identify 
less common (yet serious) adverse events. Thus, observation studies are an important addition to 
complementing RCT data with real-world information (7,11).  
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3.2 Clinical Research Organizations 
The ICH-GCP defines a CRO as a “person or an organization (commercial, academic, or other) 
contracted by the sponsor to perform one or more of a sponsor’s trial-related duties and functions” 
(12). The sponsor is the entity responsible for the “initiation, management, and/or financing of a 
clinical trial” (12).  
CROs provide clinical trial and other research support services for the pharmaceutical, 
biotechnology and medical device industries (13). The services performed by these organizations 
include investigator recruiting and training, study monitoring, data management, statistical 
analysis, auditing activities, adverse events reporting, medical writing or regulatory services.  
In the last 30 years, a significant trend towards extensive outsourcing of drug-development 
responsibilities to CROs has been observed (14). This tendency is mainly a result of the economic 
pressure that various major pharmaceutical companies have been facing due to expiring patents 
and emptier product pipelines, leading to significant job reductions (15). Consequentially, 
pharmaceutical companies are now developing new products with smaller in-house staffs, which 
increases their reliance on CROs. By contracting CROs, these companies can acquire specific 
expertise without the need to hire permanent staff or building the experience in-house, leading to 
important savings (13). Currently, it is estimated that more than 60% of all clinical studies involve 
significant outsourcing (14). The sponsors’ main reasons to outsource CRO services are shown in 
Figure 3 (15). 
 
Figure 3 – Sponsors’ reasons to outsource CRO services (Adapted from CenterWatch Vendor & Outsourcing Survey, 2005) 
(15). 
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Additionally, a wider range of services is being contracted. In 1992, site recruitment and study 
monitoring were the services most frequently contracted by the sponsors. In the following years, a 
considerable increase was observed in the use of data management, statistical analysis and medical 
writing services (14). According to a survey conducted in 2005, the services most commonly 
outsourced by CROs are depicted in Figure 4 (15): 
 
Figure 4 – Most commonly outsourced CRO services (Adapted from CenterWatch Vendor & Outsourcing Survey, 2005) 
(15). 
Nowadays, two distinct client bases drive the market for CROs: large pharmaceutical companies 
represent 60% of the market, with the majority of the work involving phase III studies, whereas 40% 
percent of the market is accounted by small biotechnology companies, which mainly outsource 
phase I and early phase II studies (14).  
 
3.3 Medical Writing Landscape  
New knowledge and information is constantly being added to the field of medicine through a 
continuously increasing number of research studies and growing clinical experience (16). To obtain 
the most of it, the information produced as a result of these studies and experience should be 
effectively communicated to various audiences, which may include physicians or other healthcare 
professionals, patients and consumers, and drug regulators.  
Medical writing involves the writing of scientific documents by writers in the field of medicine, 
known as “medical writers”. Though medical writers are not usually the ones that performed the 
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actual research, they communicate with the investigators responsible for the generation of the data 
in research studies in order to present the information in an appropriate manner. Because science 
benefits from clear and accurate reporting, the importance of medical writing cannot be 
overlooked: even carefully conducted research generating groundbreaking data can be discredited 
when poorly presented (16).  
In addition to its essential role in converting data from research studies into clear and accurate 
manuscripts reporting scientific and clinical findings, medical writing is also an important part of 
the pharmaceutical, biotechonology and medical device industries. This is because specialized 
knowledge and skills are needed to be able to produce well-structured and clearly presented 
scientific and regulatory documents required by regulatory authorities throughout the process of 
development of a drug, biological or medical device.   
In the past years, the demand for medical writing has increased. This trend follows the considerable 
expansion that has been observed in the number of research studies conducted in the biomedical 
field, which led to an increasing demand for medical writing services in order to convert the data 
generated in these studies for scientific and medical publications (15).  
Additionally, factors related to the pharmaceutical, biotechnological and medical device 
companies, as well as regulatory authorities’ requirements, have also contributed to the increasing 
demand of medical writing services. These include:   
 Various large pharmaceutical and biotechnology companies that used to have large in-
house departments of medical writers downsized their teams due to internal restructuring 
plans, leading to an increase in the outsourcing of medical writing services (15). 
 Regulatory authorities require an increasingly amount of documentation during the drug 
development process (15).  
 A higher number of new drugs and medical devices are being developed by pharmaceutical 
and medical device companies, which means that more regulatory documents need to be 
developed to submit to the regulatory authorities throughout their process of approval 
(16). 
This increase is reflected in surveys conducted to assess the demand for medical writing, which 
concluded that medical writing has doubled in size from 2003 to 2008, being the fourth most 
commonly outsourced service (15). This trend is expected to continue, as long as the amount of 
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research studies and of documentation required by regulatory authorities for the drug approval 
process keep on increasing (15). 
 
3.3.1 Types of medical writing  
The documents developed by medical writers are varied in their purpose and in the audiences 
targeted. Thus, medical writing can be divided into various types, such as (16): 
 Publication/Presentation: Consists in the development of manuscripts such as research 
articles, review articles and case reports to publish in scientific journals, as well as the 
development of abstracts, posters and presentations for scientific meetings and 
conferences.  
 Medical Journalism – Consists in the development of articles for newspapers and 
magazines. Whereas the previous type of medical writing is primarily aimed for scientific 
and medical audiences, these articles mostly target the general public and lay people. As 
such, they should be written in a simple and non-technical language.  
 Research documents – Focuses in the development of clinical trial protocols, investigator’s 
brochures, informed consent documents and study reports.  
 Regulatory documents – Comprises the development of regulatory submission 
documents, such as Common Technical Documents models (nonclinical and clinical 
overviews and summaries, safety and efficacy summaries), aggregate safety reports such 
as periodic safety update reports and annual safety reports, as well as the preparation of 
prescribing information and patient information leaflets, clinical study reports and subject 
narratives.  
 Medical Education – Involves the preparation of educational material in the form of 
textbooks and e-learning modules targeted to physicians or patients.  
 Medical marketing of healthcare products – Consists in the development of promotional 
literature such as product monographs, brochures and handouts for healthcare 
professionals, and internet content for physicians and patients. 
Because the audiences targeted (medical professionals, drug regulators, patients and general 
public) vary according to the type of medical writing and even within the same type, it is of utmost 
importance that the language and the level of technical information used is in accordance to the 
level of understanding of the respective audience. Thus, documents targeted for patients and the 
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general public must be simple and with no technical jargon, whereas documents for medical 
professionals and drug regulators can be highly technical, include scientific data and its explanation. 
Moreover, documents for regulatory submission must comply with specific formats and structures, 
and their contents must follow regulatory rules and guidelines (such as the ICH-GCP) (16). 
 
3.3.2 Peer-Review Process 
The peer review process of manuscripts prior to publication has been used for over 300 years (17). 
The International Committee of Medical Journal Editors (ICMJE) defines peer review as “the critical 
assessment of manuscripts submitted to journals by experts who are not part of the editorial staff” 
(18). Since its introduction, the peer review process has been continuously growing, correlating 
with the increasing number of manuscripts developed and submitted to journals. In the past, 
journal editors were rarely selective of the manuscripts reviewed due to the low amount they 
received. However, as the need for evidence-base medicine grew, the submissions to scientific 
journals increased to an extent that required a much higher level of selectiveness on what gets 
published in a journal. The need for peer review was also influenced by the expansion of areas of 
expertise, which became more specialized and sophisticated. Consequentially, editors could no 
longer be experts in all areas and began to seek opinions and advice from others (17). 
Nowadays, the peer-review process is used in nearly all scientific journals, and it serves three main 
purposes (17): 1) it helps to identify and select quality articles for publication while rejecting poorly 
conceived, designed and executed studies. This is accomplished by evaluating an article’s scientific 
merit, validity and methodology, its relevance to the clinical practice, the interest of the topic to 
the journal’s reader, and its overall presentation and understandability; 2) to improve the 
manuscript whenever possible; 3) to prevent malfeasance within the scientific and clinical 
community. 
 
3.3.3 Reporting Guidelines and Good Publication Practices  
Peer-review publications are among the most important outputs of any research, since they 
represent the main means of sharing the findings with the research community (19). They are 
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capable of impacting the medical practice, driving treatment decisions and patients outcomes. 
Thus, reporting of medical research should be associated with high standards of excellence. Poorly 
or unclear reporting of a study’s methodology and findings impairs its critical appraisal and 
dissemination. Additionally, inadequate reporting of medical research can lead to unclear and 
misleading results being used by patients and healthcare providers, which in turn may cause harm 
to the patients and the use of scarce healthcare resources on ineffective treatments (19).  
Thus, recommendations and guidance for the reporting of medical research are provided in 
reporting guidelines, such as the CONSORT. These guidelines aim at improving the quality of report 
of studies of various types and at helping readers to more easily understand the design, conduct, 
analysis and findings of published studies (20). The EQUATOR Network, funded by the National 
Knowledge Service of the UK National Health Service, assists in the development, dissemination 
and implementation of reporting guidelines. Following the development of the CONSORT in 1996, 
several other guidelines have been developed for other types of research studies. Examples of these 
guidelines are specified below: 
 STROBE (Strengthening of the Reporting of Observational Studies in Epidemiology) – 
guidelines for reporting observational studies; 
 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses – 
guidelines for reporting systematic reviews and meta-analyses; 
 STARD (Standards for Reporting of Diagnostic Accuracy Studies) – guidelines for reporting 
diagnostic accuracy studies; 
 CARE – guidelines for reporting case reports; 
 CHEERS (Consolidated Health Economic Evaluation Reporting Standards) – guidelines for 
reporting economic evaluations of health interventions.   
Empiric studies have demonstrated the value of following these guidelines. One particular study 
showed that the CONSORT is associated with improvements in the quality of reports of randomized 
controlled trials (21). 
In addition to the reporting guidelines described above, particularly relevant guidelines for medical 
writers aiming to publish scientific articles are the ICMJE “Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals” and the “Good 
Publication Practice (GPP) for Communicating Company-Sponsored Medical Research: GPP3”.  
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The ICMJE guidelines provide recommendations on the best practices and ethical standards in the 
reporting of research and other material published in medical journals, and the GPP3 provides 
recommendations for individuals and organizations that contribute to the publication of research 
results sponsored or supported by pharmaceutical, medical device and biotechnology companies, 
and aims at helping individuals and organizations to maintain ethical and transparent publication 
practices and to comply with legal and regulatory requirements.  
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4. Training Experience 
4.1 General Training  
At Eurotrials, training is divided into job-specific and project-specific trainings.  
My internship began with a training period comprised by a set of required job-specific trainings. 
Many of these trainings consisted in reading Standard Operating Procedures (SOPs), which are 
detailed, written instructions to be followed by employees of an organization in order to achieve 
uniformity when performing a specific function (12). Generally, there are general SOPs, applicable 
to all employees, and specific SOPs, only applicable for a particular job description.   
As a member of the Medical Writing and Biostatistics SUs, I was required to perform the job-specific 
trainings related to both these departments. On one hand, trainings such as reading the company’s 
Quality Manual, the Code of Business Conduct and Ethic and other applicable SOPs provided a 
strong basis to understand the basic procedures and the company’s organization. On the other, the 
mandatory trainings related to the activities performed in the Medical Writing and Biostatistics SUs 
were essential for a better understanding of their scope as well as to become familiarized with 
some obligatory procedures to be followed during their development. Moreover, job-specific 
trainings also included reading specific regulatory guidelines, such as ICH’s guideline on GCP (E6) 
and attending the company’s annual pharmacovigilance training, mandatory for all Eurotrials’ staff. 
This last training allowed me to understand the pharmacovigilance responsibilities of all 
collaborators, including how to properly handle relevant safety information, as well as procedures 
to adequately report safety related information to the pharmacovigilance manager in a timely 
manner.  
Project-specific trainings were related to my participation in specific projects. For example, they 
could be reading the clinical study protocol, the statistical report, or other related documents, when 
applicable. They revealed to be important to become familiarized with the projects in which I 
participated and to comprehend their purpose and objectives.  
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4.2 On-the-job Training  
Throughout my internship at Eurotrials, I was mainly involved in medical writing activities. These 
included the development of scientific articles of various types, posters to present in scientific 
congresses, medical information to publish online, and the preparation and submission of 
manuscripts to scientific journals. My participation in the Biostatistics SU was mostly based on the 
development of Statistical Reports.  
The activities in which I participated are described in the sections below. Due to confidentiality 
reasons, some studies’ results and elements are not specified.  
 
4.2.1 Development of Scientific Posters  
At professional conferences, research results are commonly presented in the form of scientific 
posters (22). A scientific poster is a visual presentation of scientific research presented in a standard 
form. In conferences, a poster may serve two main purposes: summarize the research conducted 
in a way that facilitates its communication to conference attendants (for cases in which an oral 
presentation is also programmed), or to encourage readers to want to learn more (when no oral 
presentation is planned) (23). 
Overall, a poster should be concise and present a clear message. The title is particularly relevant in 
a scientific poster, as it may be the only part that conference attendees read before approaching 
the poster. Thus, the title should be short, engaging and comprehensible to a broad audience (23). 
The poster’s layout and format are also critical and should aim to guide the readers from one 
section to another in a logical fashion, from beginning to end. To that end, the use of arrows or 
numbering to indicate the logical flow of the poster is advised. Additional general recommendations 
when developing a poster are to not use a font-size smaller than 24 points and to ensure that the 
main points are readable at eye level (23). 
The text of posters should also conform to the norms of sound scientific reporting: clarity, precision 
of expression and economy of words (23). The last norm is particularly relevant for posters due to 
their inherent space limitations, and can be accomplished through the use of figures and tables to 
summarize the findings and by adapting detailed paragraphs of the original manuscript/abstract 
into text bullets (22). By following these recommendations, the audience can more readily grasp 
the key points of the poster.  
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Activity  
During my internship, I was responsible for the development of two posters to be submitted and 
presented in a pneumology congress. Both posters were to be based on two abstracts previously 
submitted to the same congress. In addition to following the general recommendations for the 
development of scientific posters described above, the congress had specific requirements for 
preparing and submitting scientific posters. Thus, I also had to read and follow the online guidelines 
available in the congress’ website, which specified the minimum font-size, spacing, margins and 
poster orientation to be used.  
The posters were developed using Microsoft PowerPoint and submitted in the congress’ online 
platform.  
 
4.2.2 Clinical Study Reports  
The CSR is a critical document in the drug development and regulatory submission process. CSRs 
are written for regulatory authorities and follow a specific guideline issued by ICH (E3 “Structure 
and Content of Clinical Study Reports”) (24) – which structures the content of CSRs and aims at 
provide guidance in the development of a report that is complete, free from ambiguity, well 
organized and easy to review (25).  
The ICH-E3 defines a CSR as an “integrated full report of an individual study of any therapeutic, 
prophylactic or diagnostic agent conducted in patients” (24). A CSR aims to describe the rationale, 
objectives and results of a study, to include extensive details on demographic data of patients, their 
course of treatment, and the medical information collected as part of the research, as well as to 
explain how the study was conducted and the results analyzed (26). The body of a CSR should 
generally include the following topics (as defined in ICH-E3), although some may be considered as 
not applicable according to regulatory framework: 
1. Title Page; 
2. Synopsys; 
3. Table of contents; 
4. List of abbreviations and definition of terms; 
5. Ethics; 
6. Investigators and study administrative structure; 
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7. Introduction; 
8. Study objectives; 
9. Investigational plan (study design, treatments, variables, quality assurance, statistical 
methods and changes in study conduct); 
10. Study patients; 
11. Efficacy evaluation; 
12. Safety evaluation; 
13. Discussion and overall conclusions; 
14. End-of-text tables and figures;  
15. Reference list; 
16. Appendices.  
The appendices (topic number 16) are specific additions of individual regulatory authorities and 
should be available upon request according to regional regulatory requirements. They may include 
the study’s protocol, sample case report forms, information related to the test 
drugs/investigational products, technical statistical documentation, related publications, patient 
data listings, among others.  
 
Activity  
Throughout my internship, I participated in the development of CSRs for two studies related to 
investigational medicinal products. I was responsible for collecting and organizing the documents 
that comprise the CSR appendices.  
As a general rule, the compilation of the CSR appendices should begin in parallel with the 
development of the CSR. When my participation in the first CSR began, I already had some level of 
understanding on the process of appendices compilation, due to the training period performed at 
the start of my internship (which included a specific training on the development of CSRs). 
Nonetheless, to further understand and identify the documents needed to complete the 
appendices, I carefully read the ICH-E3 guideline, with a special focus on section 16, which defines 
the structure and contents of the appendices. According to this guideline, the following documents 
should be included in the appendices (24):  
1. Study information 
1.1 Protocol and protocol amendments 
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1.2 Sample case report form  
1.3 List of Independent Ethics Committees or Institutional Review Boards (plus the name 
of the committee Chair). Representative written information for patient and sample 
consent forms 
1.4 List and description of investigators and other important participants in the study, 
including a brief Curriculum Vitae or equivalent summaries of training and experience 
relevant to the performance of the clinical study 
1.5 Signatures of principal or coordinating investigator(s)  
1.6 Listing of patients receiving test drugs/investigational products from specific batches, 
when more than one batch is used 
1.7 Randomization scheme and codes (patient identification and treatment assigned)  
1.8 Audit certificates (if applicable) 
1.9 Documentation of statistical methods (includes statistical analysis plans, statistical 
reports) 
1.10 Documentation of inter-laboratory standardization methods and quality assurance 
procedures (if applicable) 
1.11 Publications based on the study 
1.12 Important publications referenced in the report 
 
2. Patient Data Listings 
2.1 Discontinued patients 
2.2 Protocol deviations 
2.3 Patients excluded from the efficacy analysis 
2.4 Demographic data 
2.5 Compliance and/or drug concentration data (if applicable) 
2.6 Individual efficacy response data 
2.7 Adverse event listings (for each patient) 
2.8 Listing of individual laboratory measurements by patient (if applicable) 
 
3. Case Report Forms 
3.1 Case Report Forms (CRFs) for deaths, other serious adverse events and withdrawals for 
AE 
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3.2 Other CRFs submitted 
 
4. Individual Patient Data Listings (if applicable) 
 
Both projects I was involved started with a kick off meeting with the sponsor. These meetings 
introduced the projects’ background and established the timelines, workflow, deliverables and 
responsibilities for the preparation of the body text of the CSR. Additionally, topics specifically 
related to the appendices were also discussed. For example, the documents to be included in the 
appendices were identified by evaluating which ones were applicable to a particular study. For 
instance, by assessing whether the study was audited, we were able to evaluate whether audit 
certificates would be necessary for that study; or, if an abstract or a poster containing study findings 
had been presented in congresses, we recognized that these publications had to be obtained. 
Naturally, the type of study also influenced the applicability of some documents: for example, the 
listing of patients receiving test drugs/investigational products from specific batches and the 
randomization scheme and codes are not applicable in observational studies. Other important topic 
of discussion was the definition of whether the CSR (and consequentially the appendices) was to 
be developed based on the sponsor’s or Eurotrials’ specific procedures. Regarding the appendices, 
this decision could impact their formatting and presentation.  
The process of compiling the CSR appendices I followed during both projects is described below: 
1. First, I had to define a list (similar to the one presented above) stating the documents 
needed to be included in the appendices. This list was adapted in accordance with the 
information discussed during the kick-off meeting, by removing the documents considered 
as not applicable for a particular study.   
2. Second, I sent the list compiled in the previous step to the parties that possessed the 
documents specified. While the sponsor was generally responsible for providing the 
majority of the necessary documentation, in studies for which the monitoring was 
performed by Eurotrials, the relevant documents had to be requested to the study’ 
monitors. Because the appendices are to be submitted to regulatory authorities in PDF 
format, it was important to request all documentation to be sent in this format.  
3. Third, I verified the documents received for accuracy. Any inconsistencies found were 
directed at the sender of the document for clarification. 
23 
 
4. Lastly, I organized the files according to the structure defined in ICH-E3, and named each 
file in accordance to Sponsor’s or Eurotrials’ procedures (as applicable). 
My participation ended when all applicable documents were obtained and considered accurate, all 
inconsistencies were adequately clarified, and every file was stored accordingly. The compiled 
appendices were then sent to the sponsor in PDF format.  
The main challenge of these activities were dealing with a great amount of documentation, and 
ensuring that all documents were obtained, accurate, and correctly organized.  
 
4.2.3 Writing of articles 
During my internship period, I was responsible for the development of three distinct types of 
articles to be submitted in scientific peer-reviewed journals: two original research articles, a 
systematic review and meta-analysis, and a narrative review. In this section, each type of article I 
was involved is briefly introduced before describing its process of development.  
 
4.2.3.1 Original Research Articles  
Original research articles are categorized as primary literature, which refers to reports of research 
conducted personally by the authors of the article (27,28). They are the most common type of 
article published in peer-review journals.  
An original research article reports new data based on original research, includes a bibliography 
review of other literature and is supported by statistical analyses (29). In these articles, researchers 
present their hypothesis or research question and the rationale for the study, detail the research 
methods, present, interpret and discuss the possible implications of the results, and draw 
conclusions based on the findings.  
These types of articles generally consist of a title, abstract, keywords, introduction, material & 
methods, results, discussion and references. This basic structure is known as the IMRAD 
(Introduction, Methods, Results and Discussion) structure (29). 
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Observational study  
This project consisted in the development of an original research article related to an observational 
study that was conducted to assess the efficacy and safety of an antiepileptic drug. The article was 
developed based on literature provided by the sponsor, comprising observational studies and 
clinical trials that also evaluated the safety and efficacy of the same antiepileptic (to establish 
comparisons with the study findings), and on a statistical report previously developed by the 
Biostatistics department, describing the study’s methodology and results. 
This was the first article developed during my internship. I read and followed the STROBE guideline, 
applicable for observational studies, which revealed extremely helpful to recognize how to 
structure the article and to identify the necessary information to report in each section.  
     
Delphi Panel 
The Delphi method was originally developed by Dalkey and Helmer in the 1950s. It is a commonly 
used and accepted method of obtaining real world data from a panel of participants regarding their 
domain of expertise. In this method, consensus regarding a particular topic being examined is 
sought from the participants (selected experts). To that end, several rounds of questionnaires are 
sent to the experts, and the anonymous responses are combined and shared with the group 
following each round, to provide feedback and to further the discussion. In the subsequent rounds, 
the experts are able to adjust their answers. Generally, the experts modify their responses as 
rounds are completed, based on the information specified by other experts participating in the 
panel. The questionnaire rounds may be repeated as many times necessary to achieve a general 
consensus (30,31).  
The main advantages of this method include the subject anonymity, which may reduce the bias of 
response due to the effect of dominant individuals and because the panelists do not need to worry 
about repercussions of their opinions, and an ease to obtain information from experts of distant 
geographic regions by using electronic communication such as e-mail to exchange information.  
 
Activity 
My participation in this project consisted in the development of an original research article aimed 
at describing a Delphi panel conducted to characterize the clinical practice of a hematological 
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disease in Portugal. The first step of this project consisted of a meeting with the Biostatistics 
department, which had developed the study’s statistical report. During the meeting, the rationale, 
objectives and methodology of the Delphi panel were explained, and the results obtained were 
specified. After becoming familiarized with the project, I attended a meeting with the sponsor, in 
which aspects such as the scope of the manuscript and the most suitable journal for submission 
were discussed, and relevant literature to develop the manuscript and to compare the results 
obtained during the panel was specified and made available. 
A particular challenge during this project was related to my lack of experience in Delphi panels and 
the fact that no specific guideline for the reporting of these panels was available. Thus, before 
beginning to write the manuscript, I read various articles of studies using the Delphi methodology 
in order to become familiarized with their reporting. Additionally, I had to acquire knowledge on 
the hematological disease of this study and the treatments used in its management. To that end, 
guidelines from entities such as the National Comprehensive Cancer Network and the National 
Institute for Health and Care Excellence regarding the management of this hematological disease 
were essential.   
The manuscript was developed based on self-searched literature, the statistical report, and an 
observational study conducted in various European countries that also evaluated the management 
of this hematological disease.  
 
4.2.3.2 Review Articles 
Review articles are considered as secondary literature, which consists of publications that rely on 
primary sources for data (such as original articles) (27,28). Their main purpose is to summarize and 
synthesize knowledge in a specific area and, as such, it is not required that the authors have 
performed the research themselves.  
Review articles provide a comprehensive summary of the research conducted on a certain topic, 
and offer a critical perspective on the state of the field and where it is heading. They are usually 
widely read (for example, by researchers looking for a full introduction to a specific field) and highly 
cited. 
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Systematic review and meta-analysis  
Globally, a substantial expansion of research output, including peer-reviewed publications and 
unpublished data has occurred. This has made it difficult for clinicians and researchers to keep up 
to date with the best research evidence and to identify the research already performed in a specific 
area (32). Moreover, following a literature search on a specific clinical question, a considerable 
number of articles is usually retrieved, which may have conflicting results and variable quality (33). 
Thus, healthcare decisions should not be based solely on the results reported by one or two studies, 
but rather take into consideration the entirety of research information available for that specific 
problematic (33).  
The points described in the previous paragraph help to understand the importance of systematic 
reviews and meta-analysis and their role in the medical context. They allow to summarize the 
outcomes of various studies and, therefore, are an exceptionally effective method to determine 
whether an intervention is efficacious or not (32). In fact, systematic reviews of RTCs are considered 
the highest level of evidence regarding research designs to evaluate the effectiveness of 
interventions (34). 
A systematic review aims to answer a specific research question through the collection and 
summarization of all empirical evidence that complies with pre-specified eligibility criteria (35). It is 
most useful when there is a substantive research question; there are a considerable number of 
empirical studies published; and there is uncertainty regarding the results (36). Systematic reviews 
can be of interventions, such as RCTs, or observational studies (case controls, cohorts). The use of 
observational studies to conduct systematic reviews has been common in areas such as sociology 
and psychology, as the great majority of studies performed in these disciplines are of observational 
nature (36).  
To be useful to other researchers and clinicians, systematic reviews should respect various aspects. 
These include: 
 Clearly specified objectives and eligibility criteria defined à priori; 
 Well explained and reproducible methodology; 
 A literature search that aims to identify all relevant studies; 
 An assessment of the validity of the included studies’ findings (risk of bias); 
 Clearly synthesized characteristics and findings of the included studies. 
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A meta-analysis is the use of statistical methods to summarize the results of the studies selected 
during the systematic review. The rational of the meta-analytic process is that the overall sample 
size is increased by pooling the results of various individual studies, which in turn increases the 
statistical power of the analysis and the precision of the treatment effects’ estimates (33). 
Moreover, meta-analyses may have sufficient power to investigate clinically important subgroups 
(37). 
The meta-analysis process can be divided into two stages. In the first stage, a measure of effect size 
and the respective 95% Confidence Interval (CI) are calculated for each individual study considered 
for the analysis. Whereas traditional hypothesis testing give information regarding statistical 
significance (i.e., were there differences in the intervention and control groups) but not necessarily 
clinical significance (i.e., was the difference observe clinically meaningful or large), effect sizes 
measure the strength of the relationship between two variables, which allows to evaluate the 
magnitude of the intervention effect (small, medium, or large) (32). The type of outcome and 
intervention examined and the data available from published trials will often define the type of 
effect size calculated. Commonly used effect sizes include odds ratios, relative risks, and 
weighted/standardized mean differences (32). In the second stage, the overall effect of the 
intervention is calculated using a weighted average of the effect size of the individual studies. A key 
point in a meta-analysis is that greater weights are given to the results of studies providing more 
information, as they are more likely to be closer to the “true effect” we are trying to estimate. 
Generally, the weights are calculated as the inverse of the variance (the standard error squared) of 
the treatment effect, which relates to the sample size and the precision of the results (33).  
The process of conducting a systematic review and meta-analysis can be divided into several steps 
(32,33): 
First step - Formulating the research question, forming hypotheses, and developing a review title. 
The formula ‘Intervention for population with condition’ is usually used to define a descriptive and 
short title.  
Second step - Definition of inclusion and exclusion criteria. The acronym PICO (standing for 
Population, Intervention, Comparison and Outcomes), proposed by Cochrane, is useful to define all 
major components before the start of the review. Additionally, defining the types of studies to be 
included and excluded (i.e., only RCTs or only observational studies, only published versions or 
published and unpublished versions), the minimum number of participants in each group 
(intervention and control), and language restrictions should also be defined a priori.  
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Third step - Literature search. It is essential to define a set of key search terms related to each 
component of PICO to identify all studies relevant to the question defined. A key aspect in this step 
is to balance sensitivity (i.e., retrieving a high proportion of relevant studies) with specificity 
(retrieving a low proportion of irrelevant studies). The search usually involves various relevant 
electronic databases (Medline, EMBASE), but can also comprise checking the references of selected 
articles, hand-searching key journals, and personal communications with experts or researchers in 
the field. 
Fourth step – Selection of the studies retrieved in the literature search, usually based on their title, 
abstract and keywords. Following this selection, the full-texts of the studies meeting the inclusion 
criteria are obtained and reviewed. It’s important that this process is performed by two or more 
independent reviewers so that the results can be discussed and the inter-rater reliability assessed. 
Moreover, the reasons for inclusion and exclusion of the studies reviewed should be recorded. 
Contacts with the study authors are often required to obtain data not specified in the article but 
that is needed for the data pooling, such as means or standard deviations.  
Fifth step - Data extraction. It’s advised to develop and use a simple data extraction form to 
summarize the information extracted from each study selected. Examples of information generally 
collected include the authors, publication year, number of participants, study design, outcomes, 
and the status ‘included’ or ‘excluded’. Similarly to the selection of studies, this process should be 
carried out by two or more independent reviewers to validate the data inserted and avoid data 
entry errors.  
Sixth step - Assessment of the studies quality. Various tools are available to perform this 
assessment, and the choice will depend on the type of study included in the review. Most of these 
tools are checklists, in which specific questions related to the study quality are specified. For 
randomized trials, the most commonly used tool is the Cochrane Collaboration’s Risk of Bias tool 
(38), and entities such as the CONSORT Statement provide various others. 
Seventh step - Analyzing and interpreting the results. Several meta-analytic software allow the 
estimation of effect sizes for meta-analyses, such as the Review Manager (RevMan) by the 
Cochrane Collaboration. The effect sizes are usually presented together with a 95% CI, both in 
quantitative form and in a graphical representation (forest plots). 
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Figure 5 – Example of a forest plot (39)  
In the forest plot example shown in Figure 5, each horizontal green squared shape represents one 
study, with the middle representing the effect size and the extremities the ends of the CI. The center 
line of the graph represents the zero mark. In this example, the left side (<0) is the side favoring the 
control, whereas the right side (>0) favors the intervention. The single black diamond in the bottom 
of the graph represents the combined effect size of all individual studies pooled together. Because 
the entirety of the diamond is at the right side of the graph, the intervention is favored over the 
control. This is confirmed by the statistically significant value of the test for overall effect (p=0.02).  
Considering to what extent the results are consistent is also important. Generally, a poor overlap 
of the CIs (horizontal lines in the figure) for the results of each included study indicates the presence 
of statistical heterogeneity. To formally determine if heterogeneity is present, the software 
commonly calculate and present heterogeneity measures. In the example shown in Figure 5, the 
value for the chi-square and the corresponding p-value, as well as the I2 index, are presented. The 
chi-square assesses whether the differences observed in the results are due to chance alone, and 
the I2 allows to quantify the heterogeneity. This index may be interpreted according to the intervals 
defined below (38): 
 0-40% - non-relevant heterogeneity; 
 30-60% - moderate heterogeneity; 
 50-90% - substantial heterogeneity; 
 75-100% - considerable heterogeneity. 
Non-statistically significant values for heterogeneity are preferred. In this example, however, the 
value for chi-squared (11.69) is statistically significant (p=0.04). Moreover, the I2 index indicates 
that we are in the presence of moderate to substantial heterogeneity. Nonetheless, heterogeneous 
studies may still be pooled together, though the results should be interpreted with caution and the 
reasons for heterogeneity explored (38).  
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Two models can be used during a meta-analysis: the fixed-effects and the random-effects models. 
In a fixed-effect analysis, it is assumed that the true effect size is the same across all studies, and 
the summary effect is the estimate of this common size. Thus, it is assumed that the true effect size 
for all studies is identical and sampling error (error in estimating the effect size) is the only reason 
behind the variation in effect sizes between the studies. In a random-effects analysis, it is assumed 
that the true effect size varies across studies and the studies in the analysis represent a random 
sample of effect sizes that could have been observed. The summary effect is the estimate of the 
mean of these effects (38).  
Both methods will provide identical results when there is no heterogeneity among the studies. 
When heterogeneity is present, a random-effects meta-analysis weights the studies more equally 
than a fixed-effect analysis and the CIs for the average intervention effect will be wider, and 
corresponding claims of statistical significance will be more conservative (38).  
Sensitivity analyses are also an important component of a meta-analysis, as they allow to explore 
the influence of biased studies and of decisions made throughout the systematic review and 
analysis processes. Usually, they consist in repeating the meta-analysis by excluding studies 
considered as having a high-risk of bias (according to the previous step), which allows to evaluate 
whether the overall results and conclusions are influenced by their inclusion. Moreover, 
consistency between the results of the primary analysis and the sensitivity-analysis strengthen the 
conclusions and credibility of the findings (40).   
Eight step - Writing process to summarize the findings and provide recommendations for medical 
practitioners (which interventions are efficacious, in which populations) and for the areas requiring 
further research, and consequently the study publication and the dissemination of the findings. 
 
Activity 
During my internship, I participated in a systematic review and meta-analysis to evaluate 
personality traits and psychopathology in adults with fibromyalgia. This project was the core of my 
internship and, consequently, the task in which I spent more hours working on. It combined 
biostatistics and medical writing, as I was involved in the statistical analysis of the results and in the 
writing of the manuscript.  
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The evaluation of personality traits and psychopathology can be made through self-assessment 
questionnaires, in which individuals answer specific questions regarding personality with a numeric 
value. Generally, these questionnaires are composed by various scales, each one evaluating a 
distinct personality trait. In this questionnaire, if the combined result of the values specified by the 
participants for the questions relating to a given personality trait are above a specific numeric cut-
off, the result is considered clinical significant. The main objective of this project was to identify the 
scales clinically elevated in the fibromyalgia population. For this systematic review and meta-
analysis, two different versions of a particular questionnaire were chosen as the intervention. 
According to the acronym PICO, the population of this study are adult patients with fibromyalgia, 
the intervention is the self-assessment questionnaire, no control group was considered, and the 
outcome were the questionnaire results.  
At the time I was assigned to this project, the literature review to identify relevant articles had 
already been performed (third step). Thus, my participation began with the selection of the studies 
based on the full-text versions and the inclusion/exclusion criteria previously defined. To that end, 
I assessed the articles’ full texts to evaluate whether the study population included fibromyalgia 
adult patients, the self-assessment questionnaire was applied (either version), and the data needed 
for the analysis was specified in the results section.  
Following this step, I developed a data extraction form that aimed at collecting the most relevant 
information from the articles complying with the eligibility criteria. This information included the 
primary author, year of publication, number of patients with fibromyalgia, study population 
characteristics, fibromyalgia diagnostic criteria, version of the questionnaire, and outcomes. As 
recommended, the sponsor simultaneously and independently evaluated the full text versions for 
eligibility, created a data extraction form and collected the data accordingly. A meeting with the 
sponsor was then scheduled, in which the data extracted by both reviewers were compared and 
the rational for the inclusion or exclusion of the articles was discussed. 
The next step was the quality assessment of the studies, which started with the definition of the 
criteria to be used to identify studies with a high risk of bias. As this was not a systematic review of 
clinical trials, for which specific criteria to assess risk of bias exists (such as the Cochrane 
Collaboration’s tool for assessing risk of bias in randomized trials (38), I had to search for risk of bias 
tools related to systematic reviews of studies reporting self-assessment questionnaire results. 
Nevertheless, no tool revealed adequate for our study. Thus, in the absence of an established and 
appropriate risk of bias tool, we had to define a set of criteria that, in our opinion, were relevant 
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indicators of each study’s risk of bias. Then, using the data extraction form, I assessed whether each 
study complied with all the criteria defined. Studies not respecting one or more criteria were 
defined has having a high risk of bias.  
The next step was defining the statistical method that would be used to perform the analysis of the 
data, which was discussed during a meeting with a Eurotrials’ Biostatistics consultant. The effect 
sizes were the means of the results for each scale, reported in the studies included in the meta-
analysis. The initial idea was to conduct the analysis using a software that allows to perform meta-
analysis of the data entered (RevMan). Nonetheless, while exploring the software, I noticed that it 
required the existence of a control group in order to perform the analysis. This revealed to be one 
of major obstacles encountered during my participation in this activity: because our aim was to 
pool the mean results reported in the individual studies solely for the fibromyalgia group, we had 
to decide on an alternative statistical method. Thus, in a new meeting, the Biostatistics consultant 
defined a set of formulas that would allow to perform the analysis and obtain the desired results 
without the need for a control group. These formulas aimed at obtaining an adjusted weighted 
mean, the respective standard error and a 95% confidence interval for each scale of the 
questionnaire, and are described below: 
?̅? =
∑ 𝝎𝒊  ?̅?𝒊
∑ 𝝎𝒊
,     (1) 
where ?̅? is the adjusted weighted mean, 𝜔𝑖 is the weight of the studies (calculated as the inverse 
of the variance) and ?̅?𝑖 is the adjusted mean of the scores of each scale,  
𝑬𝑷𝑿 ̅ =  √
𝟏
∑ 𝝎𝒊
,     (2) 
where 𝐸𝑃𝑋 ̅ is the standard error of the adjusted weighted mean, 
         𝑪𝑰 (𝟗𝟓%) = (?̅?  ± 𝟏. 𝟗𝟔 𝑬𝑷?̅?),    (3) 
where 𝐶𝐼 is the confidence interval.  
Additionally, we used the Chi-squared test to evaluate the heterogeneity of the scales across the 
studies. The following equation was used: 
𝑸 =  ∑ 𝝎𝒊  (?̅?𝒊 −  ?̅?)
𝟐,   (4) 
where 𝑘 is the number of studies. 
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This value was compared to the tabulated values of the χ² distribution to assess its statistical 
significance (values higher than the tabulated ones for a given significance level and degrees of 
freedom are considered statistically significant) and, consequently, to infer about the presence of 
heterogeneity. The degrees of freedom are the number of studies included minus one.  
Moreover, the I2 index was also calculated, in order to quantify the heterogeneity of each scale 
across studies:  
𝑰𝟐 =  
𝑸−(𝒌−𝟏)
𝑸
 × 𝟏𝟎𝟎%,    (5) 
Another obstacle was the fact that the studies selected for the analysis used two different versions 
of the questionnaire. Although both versions measure essentially the same (personality traits and 
psychopathology), the values obtained for each scale in one version are a specific and constant 
value above the other, due to the use of different normative samples. Consequentially, the cut-offs 
to define clinical significance also differ the same constant value. Thus, we had to make an initial 
correction to the values extracted from the articles so that both versions could be combined. This 
was accomplished by subtracting the specific cut-off of each version to the respective results 
reported, which allowed to obtain adjusted values representing the distance to the cut-off (positive 
values were considered clinical significant).  
All these calculations were performed using a spreadsheet program (excel). Throughout this step, 
the contact with the biostatics department was crucial to clarify doubts about the formulas and to 
successfully carry out the analysis.   
The next step was to carry out the sensitivity analyses. This consisted in repeating the analysis while 
excluding all studies identified as having a high risk of bias. Moreover, we also performed an 
additional sensitivity analysis that only included the studies using the most recent version of the 
questionnaire, to evaluate whether the results were robust to the type of version used.  
After a new meeting with the sponsor, an additional analysis involving comparisons between the 
results obtained by fibromyalgia patients and healthy volunteers in each scale was planned. In this 
case, the effect sizes were the mean differences between both groups, and, due to the existence of 
a control group (healthy volunteers), I was able to carry out the analysis in RevMan. Additionally, 
some scales presented significant levels of heterogeneity, which warranted the use of random-
effects models.   
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With the main results obtained, I began to write the first draft of the manuscript. Because 
systematic reviews and meta-analysis articles are organized differently comparing to standard 
journal articles, I had to become familiarized with their particular structure. To that end, I searched 
for guidelines and checklists that define the structure and the most important information to be 
reported, as well as for systematic reviews and meta-analysis articles published in the target 
journal. We used the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
statement from PRISMA, which consists in a 27-item checklist aimed at facilitating the transparent 
reporting of systematic reviews (41).  
 
Narrative Review 
A narrative review is a type of article aimed at objectively report the current knowledge on a specific 
topic and to base this summary on previously published literature. It provides a comprehensive 
overview and helps to place that information into perspective (42).  
Given that numerous sources of information are retrieved and their findings synthesized, these type 
of articles are extremely valuable for clinicians and other researchers. For clinicians, narrative 
reviews allow to economize time when reviewing or searching for information (e.g., patient care) 
by summarizing great amounts of information into a single article (42). For researchers, they allow 
to identify, justify and refine hypotheses and to avoid pitfalls recognized in previous research.  
Both narrative and systematic reviews are subject to systematic and random errors. The main 
feature distinguishing narrative reviews from systematic reviews is the extent to which scientific 
review methods have been used to minimize error and bias. The key differences between these 
two types of review articles are summarized in Table 1 (43,44).  
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Table 1 – Key differences between narrative and systematic reviews. 
Features Narrative Reviews Systematic Reviews 
Question Broad Specific 
Search strategy Not usually specified 
Comprehensive search conducted 
in a systematic way 
Study selection 
Process for selecting studies not 
usually specified (potentially 
biased) 
Comprehensive sources; eligibility 
criteria specified 
Study quality 
evaluation 
Variable 
Rigorous critical evaluation; 
methods to assess risk of bias 
specified 
Synthesis Often qualitative 
Quantitative (usually involving a 
meta-analysis) 
 
Reviews complying with the methods outlined in the right column are more likely to be systematic 
and to provide unbiased conclusions, whereas reviews using the review methods described in the 
middle column have conclusion that are less likely to be based on an unbiased summary of all 
relevant evidence.  
In cases where a considerable amount of quality data is available, a quantitative synthesis using 
meta-analysis in the context of systematic reviews is much more valuable than a qualitative 
synthesis in a narrative review.  
Additionally, because of more rigorous review methods, systematic reviews are more likely to 
detect methodological limitations of primary studies included and of potential sources of bias. Thus, 
they generally produce more conservative conclusions in comparison to narrative reviews. Notably, 
systematic reviews often conclude that there is a lack of quality information in the literature on a 
specific topic. Though such conclusion is generally not the one intended, it is valuable to highlight 
the areas where further research is needed (37).  
Nonetheless, narrative reviews are still of great value when the main objective is to obtain a broad 
perspective on a specific topic, rather than providing quantitative answers to specific clinical 
questions (43). Because of the limitations described above, authors should make efforts to minimize 
bias as much as possible by using proper writing and research techniques, and a high level of 
objectivity, which leads to improved utility and credibility of the publication (42). 
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Activity  
The main objective of this project was to estimate the potentially preventable cases of 
pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine in the Portuguese 
population aged over 65 years. This estimative was obtained based on data identified during a 
literature search performed by the sponsor and the main findings were presented at a pneumology 
congress in the form of an abstract and a poster.   
The article was planned to be a narrative review focusing on the current state of pneumococcal 
pneumonia hospitalizations and antipneumococcal vaccination recommendations in Portugal, in 
which the findings summarized in the previously developed abstract and poster were described and 
discussed to a greater detailed. 
 
4.2.4 Editorial Process 
The aim of most research projects is to publish them in a peer-reviewed journal. Though peer 
review can be a lengthy and exhausting process, it’s the publication of the manuscript that 
effectively validates the research developed and allows it to be shared with other researchers and 
clinicians in the field (45). Throughout my internship, I was involved in the editorial process of 
several manuscripts. My participation included the selection of the most suitable journal for a given 
manuscript, formatting the manuscripts according to the selected journal’s requirements, and 
submitting the manuscripts in the journal’s online platforms. The only stage in which I did not 
participate was the peer-review process. The steps of the editorial process that I followed for each 
manuscript are described in the sections below. 
 
4.2.4.1 Journal Selection  
One key step in the publication process is to select the most suitable journal to submit the 
manuscript (45). Choosing the right journal is essential to reach the desired target audience, for 
which the manuscript’s findings have the most interest.  
Thought I was responsible for selecting the most suitable journal for various manuscripts, the steps 
I followed were generally the same. First, I began by identifying a set of potential journals. This was 
accomplished by searching for journals that aimed to publish in the same research field as the 
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research conducted. For example, if the manuscript reported a study performed to assess the 
efficacy of an antiepileptic in the prevention of seizures in epileptic patients, I would consider 
journals publishing in the neurology area. Another valuable method to identify potential journals 
was to check the references of the manuscript to be submitted, as they were likely to be published 
in journals of the same research area.  
Following the identification of potential journals, I evaluated the ones selected according to the 
following factors:   
 Journals’ aims and scope – This information can be easily accessed in the journal’s 
homepage and allowed me to evaluate whether the research performed was a good match 
for a particular journal, as it specifies the journal’s target audience and research field. For 
instance, the Epilepsy Journal states that its main aim is “to provide the knowledge on 
epilepsy globally to the readers, promote and encourage research on epilepsy and also 
provide the latest updates on the diagnosis, treatment and management of people with 
epilepsy”. Thus, the above mentioned manuscript reporting the research on the efficacy of 
an antiepileptic would be a good fit for this journal. Complementarily, searching for articles 
similar in terms of scope to the one intended for submission also revealed to be useful to 
assess whether a particular journal was a good match. The identification of similar 
previously published papers is often a clear indicator that the research topic is of interest 
to the audience of a particular journal, increasing the chances for review (45).  
 Type of articles accepted for publication – Some journals do not accept particular types of 
articles (such as case reports). Submission to a journal that does not accept the type of 
article chosen to report the research conducted is often immediately rejected (45). Thus, it 
was of utmost importance to read the “Information for Authors” section of the journal, in 
which the types of articles accepted for publication are generally specified.  
 Word count restriction – Journals frequently define word count limits which vary according 
to the article type and across different journals. A common word count restriction is the 
4000 words limit defined for original research papers. As such, I had to ensure that the 
manuscript to be submitted did not exceed the word count limit allowed by the journals 
selected for its specific article type. This information is also specified in the “Information 
for Authors” section. 
After confirming that a manuscript was a good fit for the journals and that it complied with the 
journal’s requirements in terms of article types accepted and respective word count limits, I 
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evaluated and compared the set of journals selected with regards to various factors that help to 
identify the most adequate one. These are called the journal metrics (46), which can divided into 
three: speed, reach and impact.  
The speed relates to the journal’s performance in terms of average time to review and publish (46). 
This metric can be assessed by evaluating the title page of articles previously published in a 
particular journal, which usually state the date of submission, date of acceptance and date of 
publication. By evaluating the time elapsed between the submission and publication dates, I was 
able to infer about the speed of a journal.   
The reach relates to the geographic location of corresponding authors and journal usage (46), and 
is based on the number of downloads and number of primary authors at the country level. This 
metric assumes particular relevance when the research conducted is mainly of interest for the 
country in which it was performed (for example, the evaluation of potentially preventable cases of 
pneumococcal pneumonia in Portuguese hospitals is particularly relevant for Portuguese 
healthcare professionals and patients).  
The impact is evaluated through the journal’s impact factor (IF). Although the validity of the IF as a 
metric for journal quality is controversial, it remains the default method to determine the 
reputation of a journal (45). The IF is based on the number of times the articles of a journal are cited 
in a given year, and can be calculated according to the following formula (47): 
𝐼𝐹 =  
𝑋
𝑌
 
Where X is the number of times the journal articles were cited in a given year and Y is the number 
of citable articles published by the journal in that same year. The IF is frequently stated in the 
journal’s homepage.  
Despite its widespread use, the IF should be interpreted with caution as it may greatly vary 
depending on the research area. Articles published in an area where little research has been 
conducted will be less cited and lead to lower IFs in comparison to articles published in extensively 
researched areas. 
In addition to the journal metrics described above, I also considered factors such as the journal’s 
acceptance rate and visibility, which may also influence the choice of the journal (48). A low 
acceptance rate indicates that only the best and most relevant articles are published, whereas a 
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high visibility journal is one indexed in multiple computerized databases (such as Medline, Scielo, 
EMBASE) and allows articles in the journal to be retrieved by searching these databases.  
 
4.2.4.2 Preparing the manuscript  
After identifying the most suitable journal, a manuscript must be formatted according to the target 
journal’s requirements and sent to one journal at a time only. Submitting the same work to more 
than one journal simultaneously is a serious ethical violation (48).   
To prepare the manuscript for submission, I read and followed the submission guidelines which are 
commonly available on the journal’s website, in the ‘Information for authors’ section. These should 
be carefully followed to ensure that the manuscript is formatted in accordance to the journal’s 
requirements. The guidelines usually specify the file formats for the manuscript and figures, the 
manuscript (font-size, spacing, and margins) and reference styles to be adopted, and the main 
sections to be considered. Though variable depending on the journal and article type, the body of 
the manuscript is usually divided into Introduction, Methods, Results, Discussion and Conclusion, 
known as the “IMRAD” structure.  
 
4.2.4.3 Submitting the manuscript  
To carry out the process of submission I also referred to the journals’ submission guidelines. These 
specify the documents needed for submission (such as the cover letter, the manuscript, the tables 
and figures) and the order in which they should be uploaded in the submission platform. The cover 
letter is a short document (generally containing one or two pages) that accompanies the manuscript 
in its submission. Ultimately, the cover letter aims at influencing the editor’s decision of sending 
the manuscript for peer review. To that end, it should introduce the research conducted, its 
rationale and importance, highlight the most important findings reported, and specify the reasons 
justifying why the manuscript is a good fit for the journal and why the findings are of interest to the 
readership. Depending on the journal, the suggestion of peer reviewers (experts in the topic area 
of the manuscript and not recent collaborators or from the same institution as the authors) may 
also be requested.  
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4.2.4.4 Peer review  
After submission, the manuscript is read by an editor to evaluate its adequacy for the journal. Three 
main points are usually considered: 1) the manuscript falls within the scope of the journal; 2) the 
manuscript follows editorial policy and general guidelines; 3) the content of the manuscript does 
not present an unacceptable level of overlap with manuscripts already in press. When one or more 
of the previous conditions are not verified, the manuscript may be rejected without additional 
review. If all conditions are verified, the manuscript is sent to additional reviewers (17).  
Two main types of blinding may be used during the peer review process: the single-blinded review 
and the double-blinded review. In the single-blinded review, the authors are unaware of the 
reviewers’ identities but the reviewers know who wrote the manuscript. This type of review has 
been subject of criticism and debate due to the potential bias associated with it. In the double-blind 
review, the authors’ identity is also masked during the review process (17).   
Following revision, the reviewers return their recommendations and reports to the editor, who 
assesses them collectively and decides whether to reject the manuscript, to withhold judgment 
pending major or minor revisions, to accept it pending satisfactorily completed revisions, or to 
accept it as written (17).    
When applicable, the minor or major revisions are specified to the authors via e-mail. The 
manuscript should then be modified accordingly and a revised version should be re-submitted. This 
version will repeat all or some of the stages described above. Once a manuscript has been revised 
satisfactorily, it will be accepted and prepared for publication (17).  
This was the only step of the editorial process in which I did not participate during my internship. 
  
4.2.5 Information to publish online 
In addition to the information presented in scientific journals and congresses, a considerable 
amount of information is also generated as “web content” for medical professionals and the general 
public.  
During my internship, I also had the opportunity to participate in the type of medical writing called 
“Medical Education” (See Section 3.2.1). I was responsible for the development of a summary of 
the pneumococcal vaccination recommendations in Portugal, which was intended to be published 
online and was mainly targeted for healthcare professionals and patients.  
41 
 
The main challenge during the writing of this summary was the fact that, while all projects I had 
previously developed (research articles and scientific posters) were targeted for specialized 
audiences with a high level of understanding, this information was also meant to be read by 
patients. As such, I had to adapt the language used accordingly, by making efforts to use simple 
language only and to avoid technical terms.  
 
4.2.6 Biostatistics Activities 
My participation in the Biostatistics SU was brief and mainly based on the development of statistical 
reports. A statistical report is a document describing a study’s methodology, statistical results and 
statistical conclusions. Generally, they are divided into the following sections: 
 Introduction 
 Study objectives 
 Investigational plan  
 Study design 
 Selection of study population 
 Treatments 
 Efficacy and safety endpoints 
 Statistical methods planned in the protocol and determination of sample size. 
 Study patients 
 Demographic and other baseline characteristics 
 Efficacy results 
 Safety results 
 Statistical conclusions 
 References 
Throughout my internship, I participated in the development of statistical reports for three studies. 
My role consisted in adapting the relevant information presented in the studies’ statistical analysis 
plans and protocols, and to describe its results and conclusions. A statistical analysis plan is a 
document containing a more technical and detailed information about the main features of the 
analysis described in a study’s protocol, and includes detailed procedures for the execution of the 
statistical analysis of the primary and secondary variables and other data.  
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5. Discussion 
The activities in which I participated during my internship are listed in Table 2. 
Table 2 – Activities performed during the internship.  
Activity Number of projects 
Medical Writing   
Scientific Articles 4 
Scientific Posters 2 
Preparation and submission of manuscripts 
to scientific journals.  
3 
Clinical Study Reports (compilation of 
appendices) 
2 
Information to publish online  1 
  
Biostatistics   
Statistical Reports  3 
Meta-analysis  1  
 
As it is clear by observing the table above, the medical writing activities were the main focus of my 
curricular internship. Over the course of this 9 month period, I participated in various activities 
often developed by medical writers: development of scientific articles, preparing and submitting 
manuscripts to scientific journals, development of posters to be presented in scientific congresses, 
clinical study reports and information to publish online.  
Though there are various other activities carried out by the Eurotrials’ Medical Writing SU in which 
I did not participate, my role as a member of the Medical Writing team allowed me to recognize 
that medical writers are involved in numerous activities across the clinical development phases, 
from the conception of a study (clinical study synopsis) to the final report of the study’s findings 
and conclusions (CSRs), and including the development of clinical study protocols, patient informed 
consent forms and case report forms.  
During my internship, the close relation between medical writing and biostatistics became clear. 
The frequent interactions with the Biostatistics department (responsible for analyzing and 
providing the study results, usually in the form of statistical analysis plans and reports) revealed 
essential to ensure that the study data were correctly interpreted and reported, as well as to clarify 
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any data issues. The latter point illustrates an additional important role in which medical writers 
play a part: quality assurance. When reviewing data from statisticians or directly from investigators, 
it is possible to identify errors that were not detected earlier. Thus, medical writers should seek to 
clarify the errors identified.  
The primary objective set for this curricular internship was partially accomplished: I was able to 
acquire knowledge and experience in medical writing related activities, by actively participating in 
the development of articles, posters and CSRs. In general, I improved my ability to synthesize 
information, to interpret study data summarized in tables of statistical analysis plans and reports, 
and to present complex data in a simple and clear manner. Moreover, I became familiarized with 
the reporting guidelines applicable for each type of research study and with guidelines related to 
the development of CSRs (ICH-E3), acquired experience in using reference manager software (such 
as EndNote and Zotero), and in performing literature searches in various databases (Medline, 
Cochrane, Scielo).  
I also had the opportunity to be involved in nearly all stages of the editorial process: the 
development of manuscripts, choosing the most suitable journal, formatting the manuscript 
according to the journals’ requirements, and submitting the manuscript. The only step in which I 
did not participate was the peer-review process. This allowed me to become familiarized with the 
different stages of the editorial process and to realize that each journal has its own specific rules 
and guidelines for manuscript’ formatting and submission (some journals may require the 
submission of tables and figures separately from the article, whereas others specify that the article, 
figures and tables must be sent in a single document). I also recognized that it is generally a good 
practice to define the most suitable journal before beginning the writing process, as it allows the 
manuscript to be developed in accordance to the journal’s requirements (particularly in terms of 
maximum number of words and tables/figures, and overall structure).   
Nonetheless, I was not able to acquire the level of knowledge and experience in biostatistics that I 
first set to accomplish, as my participation in the Biostatistics department was brief and mainly 
based on the development of statistical reports. Still, I was able to gain experience in conducting 
meta-analyses, both using RevMan and Excel. 
Naturally, there were many challenges faced during my internship, related to the quick transition 
from the academic to the professional environment, my limited background on medical writing and 
the lack of experience in the development of scientific articles. The Problem-Based Learning (PBL) 
methodology adopted in the Bachelor’s Degree provided me with a set of soft-skills that revealed 
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essential to overcome the challenges encountered and contributed to the overall success of my 
internship. For the quick transition from the academic to the professional environment, skills such 
autonomy, proactivity, and adaptability were of utmost importance, as well as the experience and 
availability of my colleagues to clarify any doubt. To overcome the lack of experience in the 
development of articles, I searched for and studied several reporting guidelines applicable for 
various types of article, which allowed me to become familiar with their general structure, the 
particularities associated with each one, and the essential information to be reported in each 
section. Moreover, reading the guidelines such as the ICMJE “Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals” and the GPP3’s provided 
me a solid background on the principles that should be followed when developing and submitting 
scientific articles and to comply with legal and regulatory requirements. This greatly facilitated the 
development and submission of the articles I was responsible throughout the internship. Skills such 
as resourcefulness, critical-thinking and problem-solving were extremely helpful, particularly 
during the core project of the internship – the systematic review and meta-analysis – due to the 
many difficulties to overcome. These included the lack of an appropriate tool to assess risk of bias, 
the impossibility of carrying the analysis using a standard software allowing meta-analytic 
calculations, and the need to perform an initial correction to the values reported by both versions 
of the questionnaire. Moreover, one of the modules of the Master’s Degree in Pharmaceutical 
Medicine (“Systematic Review and Meta-Analysis”) provided me with essential background 
knowledge on this topic.  
The multidisciplinary nature of the Bachelor degree in Biomedical Sciences and the Master’s degree 
in Pharmaceutical Medicine revealed extremely valuable during the internship. The knowledge and 
terminology acquired in the fields of Pharmacology, Statistics, Physiology, Anatomy and 
Pharmacovigilance, allowed me to understand the scientific rationale behind each study, to 
interpret and critically assess the data I was working with, and to effectively communicate with my 
colleagues in the multidisciplinary environment that characterize CROs.  
Additionally, the particular setting in which my internship took place (a CRO), allowed me to 
develop a set of valuable skills for the fast-paced environment of CROs. As each project had a 
deadline that needed to be met and because I was often involved in various projects 
simultaneously, I felt the need to improve my organization and time management skills, to allow 
me to keep track of my projects, identify which ones should be prioritized, and ultimately conclude 
the tasks assigned on time. On the long-term, this allowed me to become more productive. 
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Moreover, the recognition that poor performance may impact the company’s business made me 
not only develop a sense of responsibility, but also improve my attention to detail and to review 
my deliverables more carefully. The independent quality control review of the documents I 
developed by my supervisor was also essential to ensure the quality and accuracy of my deliverables 
and to provide me with important feedback. 
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6. Conclusion 
Overall, this internship allowed me to better understand the important role of medical writing in 
health research, as an essential tool to effectively, clearly and accurately communicate the data 
generated in research studies to various audiences, ranging from healthcare professionals to 
patients. I was also able to acquire practical knowledge on how to properly report various types of 
research and to submit the developed articles to scientific journals, so that their findings may be 
shared with other researchers and clinicians.  
By complementing the knowledge acquired during the Bachelor’s degree in Biomedical Sciences 
and the Master’s Program in Pharmaceutical Medicine, the internship was a successful way to make 
the transition from the academic to the business world.  
In conclusion, with the exception of acquiring experience in the tasks associated with the projects 
and services falling under the scope of Biostatistics, all objectives initially defined for this internship 
were successfully accomplished.  
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